Unity Biotechnology has been granted a patent for a method to selectively eliminate senescent cells in fibrotic livers using a Bcl-xL selective inhibitor administered intermittently. This method can treat various senescence-associated diseases like cardiovascular disorders, pulmonary fibrosis, and osteoarthritis. GlobalData’s report on Unity Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Unity Biotechnology, Cancer treatment biomarkers was a key innovation area identified from patents. Unity Biotechnology's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Selective elimination of senescent cells in fibrotic liver
A recently granted patent (Publication Number: US11980616B2) discloses a method for selectively eliminating senescent cells in a fibrotic liver by administering a senolytic agent that includes a Bcl-xL selective inhibitor. The treatment involves intermittent administration of the senolytic agent in a treatment cycle followed by a non-treatment interval, with the non-treatment interval lasting between 0.5 to 12 months. The senolytic agent can be a small molecule inhibitor, a polynucleotide, or an oligonucleotide, such as an antisense oligonucleotide, siRNA, or shRNA.
Furthermore, the patent also covers methods for treating metabolic syndrome, specifically liver steatosis, and graft versus host disease by administering a pharmaceutical composition containing a Bcl-xL selective inhibitor as a senolytic agent. Similar to the treatment for fibrotic liver, the administration of the senolytic agent for these conditions involves intermittent cycles followed by non-treatment intervals lasting between 0.5 to 12 months. The senolytic agent can be a small molecule inhibitor or a polynucleotide/oligonucleotide, including antisense oligonucleotides, siRNA, or shRNA. This patent provides a novel approach to targeting senescent cells in various medical conditions, offering potential therapeutic benefits for patients in need of such treatments.
To know more about GlobalData’s detailed insights on Unity Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
